Protein Summary
Serine protease that degrades elastin, fibronectin, laminin, vitronectin, and collagen types I, III, and IV (in vitro) (PubMed:3198760, PubMed:2033050, PubMed:28240246). By cleaving and activating receptor F2RL1/PAR-2, enhances endothelial cell barrier function and thus vascular integrity during neutrophil transendothelial migration (PubMed:23202369). May play a role in neutrophil transendothelial migration, probably when associated with CD177 (PubMed:22266279).
- ENST00000234347
- ENSP00000234347
- ENSG00000196415
- ENST00000612112
- ENSP00000478977
- ENSG00000277804
- MBN
- MBN
- MBT
- NP4
- P29
- PR3
- ACPA
- AGP7
- NP-4
- PR-3
- CANCA
- C-ANCA
Most Knowledge About | Knowledge Value
(0 to 1 scale) | ||
|---|---|---|---|
biological term | 0.81 | ||
gene perturbation | 0.81 | ||
cellular component | 0.8 | ||
cell type or tissue | 0.76 | ||
disease | 0.65 | ||
Protein Classes
IDG Development Level Summary
These are targets about which virtually nothing is known. They do not have known drug or small molecule activities
- AND - satisfy two or more of the following criteria:
Pubmed score: 5828.42 (req: < 5)
Gene RIFs: 125 (req: <= 3)
Antibodies: 478 (req: <= 50)
These targets do not have known drug or small molecule activities
- AND - satisfy two or more of the following criteria:
Pubmed score: 5828.42 (req: >= 5)
Gene RIFs: 125 (req: > 3)
Antibodies: 478 (req: > 50)
- OR - satisfy the following criterion:
Gene Ontology Terms: 18
Target has at least one ChEMBL compound with an activity cutoff of < 30 nM - AND - satisfies the preceding conditions
Active Ligands: 19
Target has at least one approved drug - AND - satisfies the preceding conditions
Active Drug: 1